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Abstract
Background: The pharmaceutical agent pentosan polysulfate (PPS) is known to induce proliferation and
chondrogenesis of mesenchymal progenitor cells (MPCs) in vitro and in vivo. However, the mechanism(s) of action
of PPS in mediating these effects remains unresolved.
In the present report we address this issue by investigating the binding and uptake of PPS by MPCs and
monitoring gene expression and proteoglycan biosynthesis before and after the cells had been exposed to limited
concentrations of PPS and then re-established in culture in the absence of the drug (MPC priming).
Methods: Immuno-selected STRO-1+ mesenchymal progenitor stem cells (MPCs) were prepared from human bone
marrow aspirates and established in culture. The kinetics of uptake, shedding, and internalization of PPS by MPCs was
determined by monitoring the concentration-dependent loss of PPS media concentrations using an enzyme-linked
immunosorbent assay (ELISA) and the uptake of fluorescein isothiocyanate (FITC)-labelled PPS by MPCs. The
proliferation of MPCs, following pre-incubation and removal of PPS (priming), was assessed using the Wst-8 assay
method, and proteoglycan synthesis was determined by the incorporation of 35SO4 into their sulphated
glycosaminoglycans. The changes in expression of MPC-related cell surface antigens of non-primed and PPS-primed
MPCs from three donors was determined using flow cytometry. RNA sequencing of RNA isolated from non-primed and
PPS-primed MPCs from the same donors was undertaken to identify the genes altered by the PPS priming protocol.
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Results: The kinetic studies indicated that, in culture, PPS rapidly binds to MPC surface receptors, followed by
internalisation and localization within the nucleus of the cells. Following PPS-priming of MPCs and a further 48 h of
culture, both cell proliferation and proteoglycan synthesis were enhanced. Reduced expression of MPC-related cell
surface antigen expression was promoted by the PPS priming, and RNA sequencing analysis revealed changes in the
expression of 42 genes.
Conclusion: This study has shown that priming of MPCs with low concentrations of PPS enhanced chondrogenesis
and MPC proliferation by modifying their characteristic basal gene and protein expression. These findings offer a novel
approach to re-programming mesenchymal stem cells for clinical indications which require the repair or regeneration
of cartilaginous tissues such as in osteoarthritis and degenerative disc disease.
Keywords: Mesenchymal progenitor cells, Pentosan polysulfate, Heparin, Chondrogenesis, Proliferation,
Gene expression, CD146
Background
Adult mesenchymal stem cells (MSCs) are an abundant
source of self-renewing, multipotent undifferentiated
cells that can be readily isolated from bone marrow, adi-
pose tissue, muscle, and synovium. They can be serially
expanded in culture and cryopreserved almost indefinitely
without significant loss of their tissue regenerative cap-
acity [1–4]. In-vitro studies have shown that when MSCs
are exposed to the appropriate physical, chemical, or bio-
logical stimuli they will differentiate into cells of the meso-
dermal lineage, including osteoblasts, chondrocytes,
tenocytes, myocytes, and adipocytes [3–5]. Moreover,
when administered systemically, MSCs exhibit the cap-
acity to migrate to the site(s) of tissue injury, where they
can modulate inflammatory and immune-regulatory path-
ways as well as release pro-anabolic factors [6–9]. These
unique activities of MSCs have led to extensive investiga-
tions into their potential applications as biological agents
for the treatment of a variety of clinical applications [5–7].
MSCs have been considered a suitable therapy for muscu-
lar skeletal and connective tissue disorders, including de-
generative disc disease, osteoarthritis, and repair of
articular cartilage, owing to the high incidence of such dis-
orders as well as their limited capacity for spontaneous re-
pair and the limited treatment options [10–16].
As indicated, MSCs possess the ability to localize to sites
of tissue injury, suppress inflammation, and facilitate re-
pair. Moreover, there is considerable evidence to suggest
that MSCs engraft at these sites, undergo differentiation,
and synthesise an extracellular matrix consistent with the
endogenous tissue [17, 18]. However, for the regeneration
or repair of cartilaginous tissues it is important that the
initial differentiation of MSCs to chondrocytes is not
followed by further differentiation to osteoblasts, a process
that has been observed in some experimental studies
using these osteochondral precursors [19, 20].
In previous studies [21] we showed that the incubation
of STRO-1+ immuno-selected mesenchymal progenitor
cells (MPCs) with the pharmaceutical agent pentosan
polysulfate (PPS) not only improved their viability and
enhanced their chondrogenic differentiation but also
suppressed osteogenesis in vitro. In subsequent in-vivo
studies using ovine models, MPCs were formulated with
PPS and injected directly into degenerate intervertebral
discs, and were found to promote the deposition of a
new disc matrix without evidence of osteogenic differen-
tiation [22–24]. However, in these animal studies the
MPCs and PPS were always mixed together immediately
prior to administration. As such, it remained to be deter-
mined whether the positive outcomes observed repre-
sented the sum of the pharmacological activities of the
individual components or whether the mechanism of ac-
tion was via a reprogramming of MPC genetic expres-
sion mediated by PPS.
The objective of the present study was to address this
question by examining the concentration-dependent
binding and internalization of PPS by MPCs and deter-
mine if priming of the cells with the drug changed their
genetic signature.
Methods
Preparation of human STRO-1+ immuno-selected
mesenchymal progenitor stem cells
Bone marrow was collected from the posterior iliac crest
of healthy volunteers (20–35 years old) following their in-
formed consent; the procedure was approved by the
Human Research Ethics Committee of the Royal Adelaide
Hospital (RAH), Adelaide, South Australia. These aspi-
rates were used to prepare immuno-selected STRO-1+
MPCs employing procedures described previously [25].
Briefly, STRO-1+ mesenchymal precursor cells derived
from the bone marrow aspirates were isolated by STRO-1
magnetic activated cell sorting and used to establish pri-
mary cultures. The primary cultures were expanded by
trypsin-EDTA detachment and re-plating at a density of
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4.0 × 104 cells per cm2 as previously described [25].
Following 3–4 passages, the cells were harvested by
trypsin-EDTA detachment and re-suspended in culture
medium at a density of 5.0–20 × 106 cells/ml. They were
then combined with ProFreeze-CDM NAO freezing
medium (Lonza Australia Ltd., Blackburn Rd., Mt Waver-
ley, Victoria 3149, Australia) (2×) containing DMSO
(7.5%), they were control-rate cryopreserved and placed at
–80 °C overnight, and subsequently transferred to the
vapour phase of liquid nitrogen until required.
Competitive PPS enzyme-linked immunosorbent assays
(ELISAs) of culture media
The concentration of PPS in culture media was deter-
mined with a competitive ELISA using a biotinylated
monoclonal antibody (1B1) against polysulphated
polysaccharides (kindly provided by Professor Prachya
Kongtawelert, Department of Biomedical Sciences,
Chiang Mei University, Thailand).
Each well of a 96-well plate was coated with 100 μl
50 μg/ml hexadimethrine bromide (Polybrene; Sigma-
Aldrich, Sydney, Australia)) in phosphate-buffered saline
(PBS), pH 7.4, and incubated at 37 °C for 1 h. The solu-
tion was aspirated and the plate was air-dried without
washing. Wells were then blocked with 200 μl/well
blocking solution (PBS + 1% bovine serum albumin
(BSA)) and incubated at 37 °C for 1 h. The solution was
aspirated and the wells were washed with 300 μl/well
PBST (PBS + 0.05% Tween-20) three times. The plates
were flicked to remove the contents of the wells and
dried. The monoclonal antibody B1B1 was diluted 1:200
in Dulbecco’s modified Eagle’s medium (DMEM) and
used as the primary antibody solution. The PPS com-
pound (BenePharmachem, Munich, Germany) was used
to prepare a 1 mg/ml working stock and was subse-
quently diluted in DMEM to create a standard curve of
0.004–4 μg/ml. The PPS standard solutions were each
mixed with the 1B1 antibody solution in a 1:1 ratio and
incubated at 37 °C for 1 h. Aliquots of the inhibition
mixtures (100 μl) were transferred to each well and in-
cubated at 37 °C for a further 1 h. Using the same plates,
culture media samples containing PPS were mixed 1:1
with the 1B1 antibody solution in the microtitre plate
wells. The samples were aspirated from each well and
the plate washed with 300 μl/well PBST three times,
flicked, and dried. Monoclonal anti-biotin-alkaline phos-
phatase (AP) antibody (Sigma-Aldrich, Sydney, Australia,
cat. no. A-6561) was used as the secondary antibody and
was diluted 1:5000 with blocking solution and 100 μl
added to each well followed by incubation at 37 °C for
1 h. The antibody solution was aspirated and the plate
was washed with 300 μl/well PBST three times, flicked,
and dried. The AP substrate, para-nitrophenyl phosphate
(PNP; 200 μl 1 mg/ml PNP in 0.1 M NaHCO3 buffer
containing 2 mM MgCl2, pH 8.6) was added to each well
and the plates incubated in the dark for 20 min. Absorb-
ance at 405 nm was then determined with a micro-plate
reader. All assays were performed in triplicate.
Kinetics of PPS uptake by MPCs in culture
Primary MPC monolayers were established in culture as
described previously [21]. Briefly, 3.0 × 105 MPCs were
seeded into wells of 48-well plates and incubated with
DMEM containing 10% fetal bovine serum (FBS) at 37 °C
in 5% CO2 for 16 h. The media from the primary cultures
was discarded and the wells were washed with DMEM
(3 × 500 μl/well); media and washings were discarded
and then replaced with DMEM (500 μl/well) containing
gradient concentrations of PPS (0.5, 1.0, 2.5, 5, and
10 μg/ml/well). Plates were maintained at 37 °C in 95%
air/CO2 and, after 0.25, 0.50, 2, 6, 20, and 24 h, media
from individual wells were aspirated, cells washed (PBS,
0.5 ml/well) and media and washings pooled. The con-
centrations of PPS remaining in the aspirated media
and washings of the cultures at each time point was
determined using the PPS ELISA as described above.
The preparation of fluorescein isothiocyanate
(FITC)-labelled PPS
PPS (100 mg) was converted to the tetrabutyl ammo-
nium (TBA) salt by incubating with tetrabutylammo-
nium bromide (100 mg; Sigma-Aldrich, Sydney,
Australia) dissolved in 10 ml de-ionized H2O for 4 h at
ambient temperature. The PPS-TBA complex was dia-
lyzed against de-ionized water for 24 h to remove excess
salts and then lyophilized. The PPS-TBA complex
(50 mg, dissolved in 1 ml DMSO) was mixed with 1,1-
carbonyl di-imidazole (28.0 mg/0.5 ml; Sigma-Aldrich,
Sydney, Australia)) and incubated at 56 °C for 1 h. After
cooling to room temperature, hydrazine (47.8 mg;
Sigma-Aldrich, Sydney, Australia) was added and the so-
lution incubated with shaking for 16 h at 45 °C. The PPS
carboxyhydrazide complex was then reacted with FITC
(Sigma-Aldrich, Sydney, Australia) using the manufac-
turer’s instructions to convert the FITC-PPS derivative
into a TBA salt derivative. The PPS-FITC-TBA salt was
then converted to the sodium salt by mixing at 4 °C with
4.0 M NaCl (100 ml) for 16 h followed by 48 h dialysis
against water with changes every 16 h, and then lyophi-
lized. The lyophilized PPS-FITC derivative was purified
by size-exclusion chromatography on a Superdex-200
column (GE Healthcare Ltd., Sydney, Australia)
equilibrated in 0.25 molar NaCl. Column fractions were
monitored for PPS concentration using the dimethyl-
methylene blue assay [26] and FITC by fluorescence
excitation/emission at 485/538 nm. Fractions positive for
PPS and FITC fluorescence were pooled, desalted, and ly-
ophilized. The purity of the PPS-FITC complex was
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established by NMR spectroscopy (by Dr. Ronald Shim-
mon, Department of Chemistry, University of Technology,
Sydney, Australia).
PPS-FITC uptake by MPCs using fluorescence microscopy
Fluorometric assay
Primary MPC monolayer cultures were established in
six-well plates (2.5 × 105 cells/well) as described previ-
ously [21]. After 16 h, DMEM (3 ml) containing various
concentrations of PPS-FITC (0, 1.0, 2.5, 5.0, 10.0, and
20.0 μg/ml) were added to the wells and incubated at
37 °C in 5% CO2 for a further 24 h. The media were col-
lected from each well, and the cells were washed 3× with
PBS at room temperature. Media and washings were dis-
carded. The washed cells were released from the plates
with 250 μl 0.25% trypsin/EDTA at 37 °C for 10 min.
The cells and supernatant were separated by centrifuga-
tion at 500 g for 10 min, the supernatants were
discarded, and the cell pellets washed 3× with PBS
(1 ml/well). The cell pellets derived from each culture
well were re-suspended in 100 μl de-ionised H2O then
transferred to wells of black microplates. The micro-
plates were agitated for 1 h to lyse the cells in the ab-
sence of light, and the intensity of the fluorescence
emission at 538 nm determined for all added PPS-FITC
concentrations using a fluorescence microplate reader
(Labsystems Fluoroskan II, ThermoFisher Scientific
Australia Pty. Ltd., Scoreby, Australia) with de-ionised
H2O as a blank. The levels of PPS-FITC in each well
were quantified using a standard curve prepared from
the purified PPS-FITC prepared above.
Qualitative assay
MPCs (6000 cells/well) were seeded on eight-well slides
(Lab-Tek-II® Chamber Slide System, Permanox®, Grand
Island, NY, USA) and incubated at 37 °C in a 5% CO2 at-
mosphere for 16 h. DMEM media (1.0 ml) containing 0,
0.5, 1.0, and 2.5 μg/ml PPS-FITC was added to each well
and the slides incubated for a further 24 h at 37 °C. The
media were removed and the bound cells washed 3×
with 1.0 ml PBS. Media and washings were discarded
and cells fixed using 300 μg/well HistoChoice MB Fixa-
tives (Amresco, Solon, OH, USA) for 20 min at room
temperature. After washing once with PBS, the cells of
each slide were stained with 20 μg/ml propidium iodide
(PI) for 10 min at room temperature, washed 3× with
PBS, once with 70% ethanol, and 3× with absolute etha-
nol, and then viewed under UV light using a Nikon
Eclipse 80 fluorescence microscopic (Coherent Scientific,
Hilton, Australia). Cells were viewed for FITC and PI
fluorescence using excitation and emission wavelengths
of 485/538 nm for 2 s and 535/620 nm for 60 s, respect-
ively. The cell images were captured using a digital cam-
era coupled to the microscope and images analysed
using the NIS-Elements software (Coherent Scientific,
Hilton, Australia).
Assessment of MPC proliferation alone and after priming
with PPS
Triplicate cultures of passage 4 MPCs at densities of
1 × 106 cells/ml were established in 24-well plates as de-
scribed previously [21]. High-glucose DMEM contain-
ing 5 μg/ml PPS was then added to 12 wells of the
plates and an equivalent volume DMEM alone to the
remaining wells. After incubation for 24 h, media were
removed from all wells and cells were washed 3× with
PBS and then re-established in culture. After 4, 24, and
48 h, incubations were stopped, media removed and
cells washed 3× with PBS; media and washings were
then discarded. Cells were released from the plates by
trypsin/EDTA treatment, the harvested cells from each
well were re-suspended in PBS, and aliquots were then
analysed to determine MPC proliferation for each of
the culture time periods using a commercial cell count-
ing kit (Wst-8 Kit (CCK-8); Sigma-Aldrich, Sydney,
Australia) according to the manufacturer’s instructions.
As the non-PPS primed MPC cultures failed to demon-
strate significant variation in their proliferation over
the three time periods, the values obtained from each
incubation period were pooled and used as the non-
PPS pre-treatment control.
Proteoglycan synthesis by MPCs alone and after priming
with PPS
Wells of six-well culture plates were seeded with pas-
sage 4 MPCs (2.8 × 105/well) and incubated with
DMEM + 10% FBS at 37 °C in 5% CO2 for 16 h. High-
glucose DMEM containing 5 μg/ml PPS was then
added to three wells of the plates and DMEM alone to
the remaining three wells. After incubation for 24 h,
media were removed from all wells and cells were
washed twice with PBS (3 ml/well) and then re-
established in culture. The biosynthesis of proteogly-
cans (PGs) by these cells over 24 h was then
determined as previously described [21]. Briefly, media
(3 ml) containing 2.2 μCi/ml H2
35SO4 (Perkin-Elmer
Life and Analytical Science Knoxfield, Victoria,
Australia) was added to each well and plates incubated
for 48 h. The medium was removed and discarded.
Cells were washed with 3× PBS, and then collagenase
solution (Sigma Aldrich, Sydney, Australia; 500 μl,
1 mg/ml) was added to each well and the plate incu-
bated at 37 °C for 1 h to detach the cells and matrix
from the plates. The collagenase digests were trans-
ferred to 1.5-ml tubes and an equal volume of acetate-
buffered papain (Sigma-Aldrich, Sydney, Australia;
1 mg/ml) added to each tube. After incubation at 65 °C
for 1.5 h, aliquots (100 μl) of the digests were assayed
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for DNA content [27] and the remainder transferred to
1.5-ml tubes, and 40 μl 1 mg/ml chondroitin sulphate
A (Sigma Aldrich, Sydney, Australia) and 60 μl 5%
aqueous cetyl pyridinium chloride (CPC; Sigma
Aldrich, Sydney, Australia) was added. The tubes were
vortexed and then centrifuged at 11,000 rpm for 3 min
to pellet the precipitated 35S-glycosaminoglycan
(GAG)-CPC complex. The precipitates were collected
by centrifugation, washed (3× PBS), and then dissolved
in 1 ml scintillant (Perkin-Elmer Life and Analytical
Science Knoxfield, Victoria, Australia) and transferred
to a scintillation vial. The radioactivity of 35S incorpo-
rated to newly synthetized S-GAGs of the PGs was de-
termined by scintillation counting (Perkin-Elmer
Tricarb 2910TR, Perkin-Elmer Corp., Massachusetts,
USA). Results were calculated as 35S-GAG-DPM/μg
DNA as an index of proteoglycan synthesis per cell.
Monitoring of MPC phenotypic receptors by flow cytometry
Suspensions of passage 4 MPCs (2.5 × 105) derived
from three independent healthy young donors
(RAH1, RAH2, and RAH3) were seeded into each
well of a six-well plate (in duplicate) and incubated
with DMEM + 10% FBS at 37 °C in 5% CO2 for
16 h. The next day, DMEM containing 5 μg/ml PPS
was added to three wells of both six-well plates. The
remaining three wells of the same plates only re-
ceived DMEM and were used as the controls (MPCs
alone). After an additional 24 h, the cultures from
one plate were terminated. The remaining plate was
incubated for a further 24 h (i.e. a total incubation
time of 48 h). At termination, all media were re-
moved and the six wells of the plates were washed
twice with PBS (3 ml/well). Media and washings were
discarded, and MPCs were detached from wells by
trypsin/EDTA treatment; enzyme activity was
quenched and the cells were strained through a 70-
μm cell strainer (Becton Dickinson Biosciences, CA,
USA) to ensure preparation of single cell suspen-
sions. The MPC suspensions were washed with
10 ml wash buffer (Hank’s buffered salt solution + 5%
fetal calf serum (FCS)) and then centrifuged at 400 g
for 7 min at 4 °C. Cells were re-suspended in block-
ing buffer (wash buffer supplemented with 1% (v/v)
normal human serum + 1% v/v BSA) and counted in
0.4% Trypan Blue and left on ice in blocking buffer
for 30 min. Cells were then pelleted by centrifugation
(400 g for 7 min at 4 °C), and the supernatant
removed and discarded. The cell pellet was re-
suspended in 100 μl of one of the primary antibody
listed in Table 1 at a final concentration of 20 μg/ml
per tube or 100 μl neat supernatant antibody. After main-
taining the tubes at 4 °C for 45–60 min, cells were washed
twice with 2 ml cold wash buffer and centrifuged at 400 g
for 7 min at 4 °C. Cells were re-suspended in 100 μl block-
ing buffer containing the appropriate secondary goat anti-
mouse antibody or FITC-conjugated antibody at a 1:50
dilution (Southern Biotechnology, USA) (Table 1) and
incubated for 30 min and then washed twice with 2 ml
cold wash buffer at 400 g for 5 min at 4 °C. Antibody-
labelled MPCs were then re-suspended in 0.5 ml FACS
FIX (1% (v/v) formalin, 0.1 M D-glucose, 0.02% sodium
azide, in PBS) for flow cytometric analysis using a BD
FACS Canto II and Flow Data Analysis Software V10
(Becton Dickinson Biosciences, CA, USA).
Extraction of RNA from MPC cultures and genomics analysis
Cells from the three donors (RH1, RH2, and RH3) were
used for these studies. Each cell line was processed as
described above for flow cytometric analysis but cells
Table 1 Primary and secondary antibodies used for MPC ± PPS
cytometric analysis
Primary antibodies Type Origin
Stro-1 In-house antibody Provided by Prof. S.














CD44 (H9H11) In-house antibody Provided by Prof. S.
Gronthos and Prof A.
ZannettinoCD146 (CC9) In-house antibody
CD34 CD34 FITC Beckman Coulter
IM1870
CD45 CD45 FITC Beckman Coulter
IM0782U


























Provided by Dr. L Ashman
CD cluster differentiation, FITC fluorescein isothiocyanate, Ig immunoglobulin
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were detached from plates using TrypLE select (Gibco
12563-029), an animal origin-free cell dissociation re-
agent, which was then inactivated by diluting with
Hanks buffer without FCS. Cells were pelleted by centri-
fugation at 400 g for 7 min at 4 °C, and the supernatant
removed. Cells were re-suspended and washed again
with Hanks buffer then lysed using 700 μl QIAzol
(Qiagen #79306). The RNA was isolated using a MiR-
Neasy Mini Kit (Qiagen #217004) and the on-column
DNAse treatment was performed according to the
manufacturer’s instructions (RNAse free DNase set;
Qiagen #79254). RNA concentrations were measured
using a Nanodrop reader. The RNA samples were proc-
essed by automated RNASeq-FastQ sequencing using
the NEXTflex™ Rapid Illumina Directional RNA-
Sequencer (BIOO Scientific, Austin, Texas, USA); for
each sample, 300 ng of total RNA was processed using
the NEXTflex™ Rapid Illumina Directional RNA-Seq
Library Prep Kit (BIOO Scientific, Austin, Texas, USA).
Briefly, the method selects poly-adenylated mRNA with
coated beads and then converts them to strand-
preserved cDNA (via dUTP) before the ligation of
sequencing adapters and barcodes. After PCR amplifica-
tion for 15 cycles the samples were quantified by a fluor-
escence assay before pooling in equimolar ratios for
sequencing. The sample pool was sequenced by the
Illumina Nextseq 500 sequencer using a High Output v2
(2 × 75 bp) paired-end sequencing kit ((Illumina, San
Diego, USA)) as per the manufacturer’s instructions ex-
cept that the loading concentrations were reduced by
30% to 0.9 pM. The data were analysed with de-
multiplexed reads that were aligned (human hg38) using
the TopHat aligner and the differential expression of
transcripts was assessed using Cufflinks in Illumina’s
Base-space analysis cloud.
Statistical methods
All data analysis and graphical representations were per-
formed using Microsoft Excel for Mac (Microsoft version
15.33) and Prism for Mac (version 7.0b, GraphPad Soft-
ware Inc.). Parametric data were analysed using one-way
analysis of variance (ANOVA), with Tukey’s multiple com-
parison test undertaken when significant differences in
means were observed. Non-parametric data were analysed
using the Kruskal-Wallis test of median values followed by
Dunn’s multiple comparison test. Treated/non-treated
groups were compared using the two-tailed Student’s t test
followed by Mann-Whitney U tests. P values < 0.05 were
considered statistically significant. For the genomic cDNA
sequencing, analysis of statistical differences in gene levels
in cells from the 24- and 48-h primed and non-primed
MPC cultures were determined using the manufacturers’
software with q values < 0.045 being accepted as
significant. However, for the majority of gene changes
identified, statistical significance was observed at the q =
0.017 level.
Results
Kinetics of binding and uptake of PPS by MPCs in culture
The kinetics of binding and uptake of PPS by cultured
MPCs when added to the media at concentrations of
0.5–10 μg/ml was monitored by the percentage decrease
in their media levels over 24 h using the PPS ELISA. As
shown in Fig. 1, all concentrations of PPS added to the
culture media decreased over the first 0.5–2.0 h of incu-
bation with MPCs. For media concentrations of 0.5 and
1.0 μg/ml PPS, this initial decline was followed by a par-
tial release of PPS into the media over the subsequent
6–24 h (shedding period). However, for cultures spiked
with 2.5, 5.0, or 10.0 μg/ml PPS, the reduced media
levels were sustained over this period. Interestingly, cul-
tures to which 5.0 μg/ml PPS had been added demon-
strated the highest decline in media levels after 0.5 h
and only released relatively small amounts over the sub-
sequent 24-h period (Fig. 1). These observations suggest
a rapid binding of PPS to cell surface heparin receptors,
followed by a time- and concentration-dependent shed-
ding and uptake by the MPCs over the 24 h of culture
[28, 29]. Moreover, under the conditions used for these
cultures, optimum uptake of PPS by MPCs was found to
occur with a medium concentration of 5.0 μg/ml.
As the PPS ELISA was not sufficiently sensitive to
evaluate the amounts of PPS associated with the MPCs
Fig. 1 Kinetics of uptake of various concentrations of pentosan
polysulfate (PPS) (0.5, 1.0, 2.5, 5, and 10 μg/ml/well) by 3.0 × 105
MPCs/well maintained in monolayer cultures for 24 h. The
concentration of PPS remaining in the culture media after 0.25, 0.50,
2, 6, 20, and 24 h was determined using ELISA. Note the rapid
decline in PPS media concentrations within 2 h of culture followed
by shedding of PPS into the media with the 0.5 and 1.0 μg/ml
concentrations. The media concentration of 5.0 μg/ml exhibited the
highest uptake by the MPCs over the 24-h culture period
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following their removal from culture, we used the PPS-
FITC preparation and a fluorometric assay to assess the
amounts of PPS associated with the MPCs. This was
coupled with fluorescence microscopy to identify the
intra-cellular distribution of PPS over the indicated
time points. The results of these studies are shown in
Figs. 2 and 3. As is evident from Fig. 2, significantly
higher levels of PPS-FITC were associated with the
MPCs after 24 h of culture with 5.0 μg/ml than with
1.0 μg/ml (p < 0.004), 2.5 μg/ml (p < 0.012), or 20 μg/ml
as a trend (p < 0.054). However, significant difference
could not be demonstrated between media
concentration of 5.0 and 10.0 μg/ml using the PPS-
FITC fluorometric assay.
Qualitative studies of the interaction of PPS-FITC
with MPCs using fluorescence microscopy together
with co-staining of the preparations with the selective
nucleus stain PI showed that, after 16 h of culture, the
PPS-FITC was largely located within the nucleus of the
cell (Fig. 3).
Although the kinetic and fluorometric studies on the
uptake of PPS by MPCs suggested that with media con-
centrations of 5.0 μg/ml more than 50% of the agent was
bound and internalised by the cells, the culture periods
used never exceeded 24 h. A study was therefore under-
taken to monitor MPC proliferation when the cells were
cultured alone or after pre-incubation (priming) with
5.0 μg/ml PPS for 4, 24, and 48 h. The results of this
study are shown in Fig. 4 where it is evident that MPCs
primed with PPS increased proliferation after 48 h to a
significantly higher extent than non-primed MPCs (p <
0.028). As an earlier study [21] had reported that co-
cultures of MPCs with PPS promoted chondrogenic dif-
ferentiation, we next investigated the biosynthesis of
PGs of MPCs alone and after pre-culturing with PPS as
described for the proliferation study.
The results of this experiment are shown in Fig. 5 and
demonstrate that the MPCs primed with PPS increased
de novo PG biosynthesis to a greater extent than when
MPCs were cultured alone (p < 0.005). Since the PPS
priming process was known to promote MPC prolifera-
tion (Fig. 4), we normalized the incorporation of 35SO4
Fig. 2 Concentration-dependent uptake of PPS-FITC by MPCs
(2.5 × 105 cells/well) determined using the fluorometric assay.
Highest uptake was observed with PPS-FITC concentrations of
5.0 μg/ml which were significantly different to 1.0 and 2.5 μg/ml.
ap < 0.004; bp < 0.012. FITC fluorescein isothiocyanate, PPS
pentosan polysulfate
Fig. 3 Fluorescence microscopy images of MPCs (6000/well) cultured with 2.5 μg/ml PPS-FITC for 24 h, fixed in Histochoice MB/ethanol and
stained with propidium iodide. a A 2-s exposure image of the MPCs outlined by the low-level background autofluorescence and the higher
emission arising from the PPS-FITC located within the cells (arrows). b The same field as a, but with 60-s exposure with excitation at 535 nm
confirming the presence of PPS-FITC within the nucleus of the MPCs (arrows). FITC fluorescein isothiocyanate, PPS pentosan polysulfate
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into the S-GAGs of the newly synthetized PG relative to
cell numbers (DNA content).
In view of these findings, we next sought to determine,
using flow cytometry, if the PPS priming process also in-
duced changes in the MPC cell surface phenotypic anti-
gens after culturing the primed and non-primed cells for
24 and 48 h. The results of these studies are shown in
Fig. 6 and Additional file 1, where the net differences be-
tween primed and non-primed MPC antigen levels were
calculated for each donor and expressed as their delta
change. Figure 6 depicts graphically the total delta
changes that occurred in surface antigen levels for each
donor over the 24- and 48-h culture periods. As is
shown, donors RAH2 and RAH3 exhibited patterns of
changes with marked decreases in the CD73, CD90,
CD105, and CD44 surface antigens of between 15–30%.
However, expression of CD146 on MPCs from donor
RAH3 declined by more than 50%. MPCs from donor
RAH1 were found to be less responsive to the priming
procedure but still exhibited the same pattern of decline
in the characteristic MPC surface phenotype receptors.
Interestingly, the STRO-1 marker used to isolate the
MPCs from bone marrow aspirates was not markedly af-
fected by the priming step; only donor RAH3 exhibited
a 10% decrease, with the cells from the other two donors
showing minimal change in expression of this antigen
following the PPS priming procedure. The low levels of
the hematopoietic and monocyte cell markers CD34,
CD45, and CD14 were not affected by PPS priming,
suggesting preservation of the mesenchymal cell lineage
(Fig. 6).
Additional evidence to support the finding that prim-
ing of MPCs with PPS mediated altered gene expression
by these cells was provided by isolating the RNA ex-
tracted from MPCs of the three donors after culturing
for 24 and 48 h and undertaking RNASeq-FastQ sequen-
cing. The results of this study are shown in Tables 2 and
3, which record the mean statistically significant gene
changes for the three donors that were detected between
their primed and non-primed MPCs after 24 and 48 h of
culture. Using internet-based gene search engines, the
proteins encoded by these genes are also identified in
Tables 2 and 3. These datasets show that after the initial
24 h of culture only four genes were upregulated and 16
downregulated (Table 2) by the priming process.
However, after 48 h 16/42 genes were upregulated and
26 downregulated.
Fig. 4 Proliferation of non-primed and pentosan polysulfate (PPS)
(5.0 μg/ml)-primed mesenchymal progenitor cells (MPCs) over 4, 24,
and 48 h determined using the Wst-8 assay kit. As no significant
differences in proliferation were observed for the non-primed MPCs,
the values for 4, 24, and 48 h were combined. Primed MPCs cultured
for 48 h were significantly different from the pooled non-primed
cultures (ap < 0.028). A450 absorbance at 450 nm
Fig. 5 Biosynthesis of PGs determined by the incorporation of 35SO4
into their sulphated glycosaminoglycans (35S-GAG) in 24-h cultures
of non-primed MPCs and MPCs primed with pentosan polysulfate
(PPS). Primed MPCs synthesised 40% more PGs than non-primed
MPCs after the 24-h culture. ap < 0.005
Fig. 6 Graphical representation of the combined changes induced in
mesenchymal progenitor cell (MPC) characteristic surface antigens
expressed on cells from three donors (RAH1, RAH2, and RAH3) that
had been cultured for 24 and 48 h with and without priming with PPS.
The raw data obtained by flow cytometric analysis is shown in
Additional file 1. Delta represents the total difference (as a percentage)
for each donor between primed and non-primed MPC antigen values.
CD cluster differentiation
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Discussion
This study has shown that priming of MPCs with PPS
results in the initial binding of the drug to the cell sur-
face receptors accompanied by partial shedding, and
then internalization and migration to the cell nucleus
where it influenced gene and protein expression. The ex-
tent of changes induced in MPC cell surface markers by
the PPS priming step for the three donors was found to
be variable (Fig. 6). Indeed, differences in gene expres-
sion by bone marrow-derived MSCs from different do-
nors have been previously reported as a potential problem
for their routine application in clinical practice [30]. This
inter-donor variability has also been attributed to a variety
of other factors, including the inherent heterogeneity of
the MSC populations isolated from different individuals,
the duration of their culture expansion, and the period
and nature of their storage [31–33]. The MPCs used in
the present study were all within the age range of 20–35
years, were selected on the basis of their expression of
STRO-1, and were subjected to similar culture and storage
conditions to minimize inter-donor cell variability.
Table 2 Gene expression changes induced by 24-h cultures
of MPCs with 5.0 μg/ml PPS relative to identical cultures of
non-primed MPCs
Gene Fold change Regulation Primary functionsa
ACTA2* 1.21 Down Encoding actin-2 protein a
member of the actin family
which collectively are
responsible for cell motility,
structure and integrity.
ADAMTSL4 0.77 Down Encodes the protein ADAMTS4
which lacks a C-terminal TS
motif but when proteolytically
processed generates the mature
proteinase that degrades
aggrecan, a major component
of hyaline cartilage.
ANK1* 2.79 Up Encoding the protein Ankyrin-1
a member of the Ankyrin
family that play key roles in
cell motility, activation, and
proliferation.
COL11A1* 1.21 Down Encoding one of the alpha
chains of type XI collagen.
COL5A3* 2.22 Up Encodes one of the alpha
chains of type V collagen
COMP* 1.08 Down COMP gene provides the
instructions for making the
COMP protein, an important
regulatory component of the
extracellular matrix.
DACT1 1.28 Down Encodes a protein member of
the Dapper family. It interacts
with and positively regulates
dishevelled-mediated signalling
pathways during development
and is an antagonist of
beta-caterin.
ENPP1 0.58 Down Encoded protein is type II
transmembrane glycoprotein




FLG* 1.82 Down The FLG gene provides
instructions for making the
large protein profilaggrin.
GREM2 0.64 Down Encodes a member of the
BMP antagonist family likely
by binding to BMPs
HSPB7* 1.56 Down Encodes a member of the heat
shock beta-7 protein family
LARGE 0.94 Down Encodes members of the N-
acetylglucosamine-L-transferase
protein family responsible for
glycosylation of glycoproteins
and glycosphingolipids.
LMOD1 0.52 Down Encodes the leicmodin 1
protein that has a putative
membrane-spanning region
and two types of tandemly
repeat blocks.
Table 2 Gene expression changes induced by 24-h cultures
of MPCs with 5.0 μg/ml PPS relative to identical cultures of
non-primed MPCs (Continued)
Gene Fold change Regulation Primary functionsa
LOXL4 0.64 Down Encodes a member of the lysyl
oxidase family essential for the
biogenesis of crosslinks of
matrix collagens and elastins.
LRRC15 0.76 Down Encodes the leucine rich repeat
containing 15 protein that
constitute regions of the
small proteoglycans.
MRVI1 0.83 Down Encoding protein MRVI1, a
substrate of cGMP-dependent
kinase-1(PKG1).
SCUBE3 0.86 Down Encodes Signal peptide-CUB
and EGF-like Domain-containing
Protein3.
SVIL 0.64 Up Encodes the protein Supervillin
which is tightly associated with
actin filaments and plasma
membranes.
SYNPO2 1.06 Down Encodes Synaptodin 2-like
protein, GO annotations
include actin binding.
TM4SF1 0.72 Up Encodes a member of the
transmembrane 4 superfamily
that mediate signal transduction
in the regulation of
development, activation,
and growth.
a From Gene Cards Human Gene Database Index, Weizmann Institute of
Science, 234 Herzi Street, Rehovat 7610001, Israel
* Confirmed via alternative analysis (Star/DESeq)
ADAMTS a disintegrin-like metalloproteinase with thrombospondin motifs,
COMP cartilage oligomeric matrix protein, GO gene ontology,
MPC mesenchymal progenitor cell, PPS pentosane polysulfate
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Table 3 Gene expression changes induced by 48-h cultures of MPCs with 5.0 μg/ml PPS relative to identical cultures of non-primed MPCs
Gene Fold change Regulation Primary functionsa
ABCA8 2.6 Up The ABCC8 gene provides instructions for making the sulfonylurea receptor 1 (SUR1) protein.
The SUR1is a subunit of the ATP-sensitive potassium (K-ATP) channel.
ABI3BP 0.9 Up Encodes the ABI family member 3 (NESH) binding protein. GO annotations of this gene include
heparin and collagen binding.
ACAN 0.8 Up Encoding for the Aggrecan core protein, also known as cartilage-specific proteoglycan core protein
(CSPCP) or chondroitin sulfate proteoglycan 1.
ASNS* 1.1 Down The ASNS gene encodes the enzyme asparagine synthetase (EC 6.3.5.4 )
CACNA2D1 1.1 Up Encoding calcium voltage-gated channel auxiliary subunit alpha2delta 1 that mediates calcium
channel regulatory activity.
CBS 1.0 Down Cystathionine β-synthase (CBS; l-serine hydro-lyase) adding homocysteine homocystinuria.
CD74 2.0 Up HLA class II histocompatibility antigen gamma chain also known as HLA-DR antigens-associated
invariant chain or CD74.
CHI3L1 1.5 Up Chitinase-3-like protein 1, also known as YKL-40, is a secreted glycoprotein.
CNN1 0.7 Down Encodes a matricellular protein also known as epididymis protein 1 that induces fibroblast
senescence and has been reported to restrict fibrosis in cutaneous wound healing.
COMP 3.2 Down COMP gene provides the instructions for making the COMP protein, an important regulatory
component of the extracellular matrix.
CRISPLD2 0.8 Down Cysteine rich secretary protein LCCL domain 2, exhibits significant LPS binding affinity.
DDIT4 0.7 Down DNA damage inducible transcript 4 regulates cell growth, proliferation and survival via inhibition
of the activity of the mammalian target of rapamycin complex 1 (mTORC1).
FLG 1.2 Down The FLG gene provides instructions for making the large protein profilaggrin
FOSB 101.0# up FosB transgene is associated with the induction of the AP-1 complex. FosB interacts with Jun
oncoproteins enhancing their DNA binding activity.
GGT5 1.8 Up Encodes the gamma-glutamyl-transpeptidase protein family. After post-translational modification,
the protein can convert Leukotriene C4 to Leukotriene D4.
FST 0.7 Up Encodes Follistatin, also known as activin-binding protein. Its primary function is the binding
and bioneutralization of members of the TGF-β superfamily.
GHRL 84.6# Down Encodes Growth Hormone protein releasing peptides protein.
HIST2H3A 99.4# Up Encodes Histone Cluster 2, H3a protein. Histones play a central role in transcription regulation,
DNA repair, and regulation of gene expression.
HMGA1 0.6 Up Encodes High Mobility Group AT-Hook 1 that regulates inducible gene transcription.
HMGA2 0.8 Up Encodes High Mobility Group AT-Hook 2, a protein coding gene which contains structural DNA
binding regions that may act as transcriptional regulating factors.
IGF2 1.6 Up Encodes the Insulin-Like Growth Factor 2 protein family that play essential roles in growth and development.
LARGE 0.8 Down Encodes members of the N-acetylglucosaminyltransferase protein family responsible for glycosylation
of glycoproteins and glycosphingolipids.
LRRC15 1.8 Down Gene encoding Leucine Rich Repeat Containing 15 Proteins. GO annotations related to this gene
include collagen binding and laminin binding.
MASP1 1.9 Down Gene encoding mannan binding lectin serine peptidase 1 that regulates the lectin pathway
of complement activation.
METTL7A 1.4 Up Encodes Methyltransferase Like 7A protein. GO annotations related to this gene include
methyltransferase activity and S-adenosylmethionine-dependent methyltransferase activities.
MTHFD2* 0.9 Down Encodes methylenetetrahydrofolate dehydrogenase (NADP + dependent) 2 enzyme, activities
that allows binding of NAD.
NFATC2 1.8 Down Encodes for Nuclear factor of activated T-Cells 2 protein that resides in the cytosol and only translocate
to the nucleus upon T-cell receptor stimulation where it becomes a member of the nuclear factors of
the activated T-cell transcriptional complex.
OLFML2A 1.7 Up Encodes for Olfactomedin-Like 2A protein. GO annotations related to this gene include protein
homodimerization activity and extracellular matrix binding.
PAMR1 1.2 Up Encoding peptidase domain containing associated with the muscle regeneration 1
Wu et al. Stem Cell Research & Therapy  (2017) 8:278 Page 10 of 15
Nevertheless, the magnitude of change in MPC surface
marker expression induced by the PPS priming step for
these three donors was found to be quite variable, suggest-
ing that individual genetic variations may represent a
dominant role. However, apart from STRO-1, the markers
CD73, CD90, CD105, CD44, and CD146 were all observed
to decline following PPS priming of the cells.
Human MSC monolayer cultures incubated with
transforming growth factor (TGF)-beta for 7 days have
been reported to undergo a similar downregulation of
the surface antigens CD44, CD90, and CD105, a finding
that was interpreted to signal an early phase of their de-
differentiation to the chondrogenic phenotype [34]. We
also observed a strong decline in CD146 antigen presen-
tation on PPS priming, particularly for MPCs isolated
from donor RAH3. The transmembrane protein CD146
is receptor highly expressed by endothelial cells [35] and
on the surface of perivascular cells, which have recently
been proposed as the source of MSCs within the peri-
vascular niche of bone marrow [36]. Moreover, a recent
study has provided compelling evidence that CD146 is a
high-affinity netrin-1 receptor on endothelial cells [37].
Netrin-1 is a neuronal guidance molecule that promotes
angiogenesis and vascular development of the endothe-
lium following interaction with CD146 [36, 37]. In
addition, expression of CD146 is associated with popula-
tions of human MPCs that promote the establishment of
bone marrow elements, and enhance osteogenic differ-
entiation and bone deposition when these cells are im-
planted subcutaneously into immune-deficient mice
[38]. The present observation that CD146 expression by
MPCs was markedly downregulated by PPS priming
would therefore be consistent with our previous obser-
vations of reduced osteogenesis of MPCs when cultured
or co-formulated with this agent in vitro [21] and in vivo
[22–24].
Although many of the functions of the proteins
encoded by the genes identified by RNA sequencing ana-
lysis could not be obviously assigned, the changes in the
genes encoding the aggrecan core protein, IGF2, alpha
chain type V collagen, FosB transgene, COMP, the pro-
teinase ADAMTS4, and type II collagen alpha chains
Table 3 Gene expression changes induced by 48-h cultures of MPCs with 5.0 μg/ml PPS relative to identical cultures of non-primed MPCs
(Continued)
Gene Fold change Regulation Primary functionsa
PHGDH* 1.1 Down Encoding D-3-phosphoglycerate dehydrogenase (catalyses the transition of 3-phosphoglycerate
into 3-phosphohydroxypyruvate, which is the committed step in the phosphorylated pathway
of L-serine biosynthesis. It is also essential in cysteine and glycine biosynthesis.
PIM1 0.8 Down Encoding Proto-oncogene serine/threonine-protein kinase Pim-1. It plays a role in signal transduction
in blood cells, contributing to cell proliferation and survival.
POM121L9P 2.9 Up This gene encodes a transmembrane protein that localizes to the inner nuclear membrane and forms
a core component of the nuclear pore complex, which mediates transport to and from the nucleus.
PSAT1 1.8 Down Encoding spermidine/spermidine Ni-acetyltransferase 1 which is a rate limiting enzyme in the catabolic
pathway of polyamine metabolism.
PTX3 1.2 Up Encoding pentraxin-related protein PTX3 also known as TNF-alfa induced protein 5. The expression
of this protein is induced by inflammatory cytokines in response to inflammatory stimuli in several
mesenchymal and epithelial cell types. It also plays a role in angiogenesis and tissue remodelling.
SLC38A1* 0.9 Down Encoding sodium-coupled neutral amino acid transporter 1, production of which plays an essential
role in the uptake of nutrients, energy production, chemical metabolism, and detoxification.
SLC7A11 1.3 Down Encoding solute carrier family 7 member 11 protein that is highly specific for cystein and glutamate
amino acids.
SLC7A5 0.8 Up Encoding solute carrier family 7 member 5 protein that transports large neutral amino acids.
SVIL 0.7 Up Encodes Supervillin. The gene product is tightly associated with both actin filaments and plasma
membranes, suggesting a role as a high-affinity link between the actin membranes, suggesting a
role as a high-affinity link between the actin and the membrane.
THSD4 0.5 Up Encoding thrombospondin type-1 domain containing protein 4. The thrombospondin family members
are adhesive glycoproteins that mediate cell-to-cell and cell-to-matrix interactions.
TMEM200A 0.8 Down Encoding transmembrane protein 200A
TPPP3 122.5# Down Tubulin polymerisation promoting protein family member 3 a protein encoding gene.
GO annotations of this gene include tubulin binding.
aFrom Gene Cards Human Gene Database Index, Weizmann Institute of Science, 234 Herzi Street, Rehovat 7610001, Israel
*Confirmed via alternative analysis (Star/DESeq)
#Fold-change overestimated due to ‘zero’ measurement in one sample
ADAMTS a disintegrin-like metalloproteinase with thrombospondin motifs, COMP cartilage oligomeric matrix protein, GO gene ontology,
MPC mesenchymal progenitor cell, LPS lipopolysaccharide, PPS pentosane polysulfate, TGF transforming growth factor
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provided are consistent with increased chondrogenic dif-
ferentiation of MPCs. For example, aggrecan core pro-
tein is necessary for the biosynthesis of PGs [39] and its
upregulation is consistent with the known elevation of
their biosynthesis by MPCs after PPS priming. The down
regulation of the ADAMTSL4 gene could also be con-
sidered as beneficial for the deposition of a cartilaginous
matrix as the protein it encodes is responsible for the
degradation of PGs [39]. In addition, the upregulation of
type V collagen could be significant as this protein is a
contributor to the assembly of collagen fibres during cell
growth and matrix assembly [40]. On the other hand,
the downregulation of the COMP genes was unexpected
since this protein is an abundant component of the car-
tilage extracellular matrix. However, studies with human
MSCs have shown that enhancement of COMP gene ex-
pression did not increase the transcript levels of the
chondrogenic markers Sox9 or aggrecan, suggesting that
the role of COMP in matrix formation occurs at the
post-transcriptional level [41]. Notably, the IGF2 gene
was found to be strongly upregulated. As the proteins
encoded by this gene play significant roles in the growth,
differentiation, and survival of connective tissue cells, in-
cluding articular cartilage [42], its elevation is consistent
with the present study and our previous report on MPC
chondrogenesis mediated by PPS [21]. The RNASeq-
FastQ sequencing data also indicated that the FosB
transgene was strongly upregulated by the priming
process. Numerous studies have shown that the Fos
genes are involved in the formation of heterodimeric
complexes with members of the jun family of proto-
oncogenes (c-jun, junB, jun D) to form the AP-I promo-
tor complex required for gene transcription [43].
Following binding to consensus sequences in the regula-
tory regions of DNA, the Fos-Jun/AP1 complex
mediates transcription pathways responsible for critical
cell functions, including differentiation and turnover of
the extracellular matrix [44].
A related sulphated glycosaminoglycan, heparin, is
known to bind and interact with a variety of cells where
it also localizes in the nucleus and modifies gene expres-
sion [31, 32, 45–48]. Moreover, heparin has been used at
low concentrations (<200 ng/ml) as a supplement for
the culture expansion of embryonic stem cells [49, 50]
and MSCs [51]. However, in a recent study which used
human bone marrow-derived MSCs [52], it was demon-
strated that when serial cultures of these cells were sup-
plemented with heparin at a concentration equivalent to
that used in the present study (500 μg/ml), cell growth
was strongly retarded and MSC morphology and genetic
expression modified to a senescent phenotype. These
conflicting findings may be explained by the structural
differences between these two polymers.
Like heparin, PPS is a poly-anion, but is not a glycos-
aminoglycan since it has a backbone structure consisting
of repeating beta-D-xylanopyranose units to which a me-
thyl glucopyranosyluronic acid ring is attached laterally
every 9–10 xylanopyranoses units (Fig. 7). The xylanopyr-
anose backbone required for the synthesis of PPS is ex-
tracted from Beech wood (Fagus sylvatica) hemi-cellulose,
is first sulphate-esterified, and then fractionated to obtain
the required molecular size. This semi-synthetic process
affords a water-soluble poly-dispersed pharmaceutical
preparation with a weight average molecular weight
(MW) of 5700 Da and a high negative charge conferred by
the large number of sulphate ester groups localised along
its xylanopyranose backbone [53].
In contrast, native heparin is a structurally heteroge-
neous biopolymer that consists essentially of variably
spaced repeating units of either 2-O-sulphated iduronic
acid and 6-O-sulphated and N-sulphated glucosamine
sugar rings linked glycosidically [54]. Commercially
Fig. 7 Structural formula of the repeating unit of the poly-dispersed PPS. On average, a single sulphated 4-O-methyl-glucopyranosyluronic acid
ring is attached laterally via an oxygen linkage to the 2 position of every sulphate-esterified 9–10th xylanopyranose unit of the polymer. From the
molecular weight distribution of 1800–17,000 Da determined by size exclusion chromatography [44], N can be estimated as 0.5–6.0
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available heparin is more poly-dispersed than PPS with
an averaged molecular weight ranging between 3000 to
30,000 Da [53] but is the most highly sulphated naturally
occurring glycosaminoglycan with 2.7 sulphate groups/
disaccharide unit [54]. However, its charge density is less
than that of PPS which on average contains 3–4 sulphate
groups/disaccharide unit (Fig. 7).
Notwithstanding these significant molecular, charge,
and conformational differences, PPS, because of its poly-
anionic structure, does exhibit some heparin-like
pharmacological activities. Although it is a weaker anti-
coagulant than heparin, PPS is a strong fibrinolytic and
lipolytic agent [52, 54]. These pharmacological activities
resulted in its original clinical applications in the 1950s
for the treatment of thrombotic and arteriosclerotic vas-
cular disease [55]. However, over the intervening years,
PPS has been shown to be effective for the management
of more diverse medical indications, including interstitial
cystitis [56], soft tissue inflammation [57], osteoarthritis
[58–60], and Ross River Virus-related arthropathies [61].
In our earlier in-vitro studies, MPCs were cultured with
PPS at various concentrations including 5.0 μg/ml, but for
up to 10 days [21]. With the longer incubation periods,
gene expression of Sox-9 and Aggrecan by MPCs was not
significantly elevated relative to MPCs alone until day 7.
In addition, expression of type II collagen was not signifi-
cantly increased until day 10, when type X collagen,
RUNX2, and Noggin gene expression was also suppressed
[21]. These earlier RNA studies suggest that the present
protocol of 24-h priming of MPC with PPS followed by
maintaining cultures for up to 48 h prior to determination
of gene expression may have been too short to establish
the lifetime of genetic modifications. We therefore ac-
knowledge that the maintenance of our PPS-primed MPC
cultures for only 48 h represents a limitation of the
present study. However, using an ovine model of disc de-
generation induced by lumbar microdiscectomy we have
demonstrated that PPS-primed MPCs when embedded in
biodegradable collagen sponges implanted into the degen-
erate discs promoted the deposition of higher levels of
proteoglycans and tissue repair after 6 months, compared
with the injured disc injected with non-primed MPCs
[62]. We consider that this in-vivo study supports our
proposition that PPS-primed MPCs retained their
modifying effects on gene and protein expression beyond
the 48-h experimental period used in the present study.
Conclusions
These studies have shown that pre-incubation of MPCs
with 5.0 μg/ml PPS for only 24 or 48 h was sufficient to
invoke significant changes in their gene signature and
protein expression consistent with enhanced prolifera-
tion and differentiation to the chondrogenic phenotype.
The PPS priming step was undertaken at the
penultimate phase of MPC culture expansion, a proced-
ure that eliminated the necessity of combining the re-
quired quantities of the two agents at the time of clinical
application and thereby eliminating the possibility that
‘free’ PPS was co-administered with the progenitor stem
cells. Furthermore, from the results of the present study,
together with the positive outcome of our animal model
study [62], we conclude that pre-culturing of MSCs with
agents such as PPS could provide an alternative method
for reprogramming these cells to promote their differen-
tiation towards a targeted phenotype that may be
required for a specific medical indication, rather than
their co-administration with agents that may independ-
ently be associated with undesirable side effects.
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Additional file 1: (A–E) Surface antigen expression of MPCs derived
from three donors (RAH1, RAH2, and RAH) when cultured for 24 and 48 h
with and without priming with 5.0 μg/ml PPS. Delta change represents
the percentage change in antigen levels mediated by the PPS priming
step. (DOCX 18 kb)
Abbreviations
ADAMTS: A disintegrin-like metalloproteinase with thrombospondin motifs;
AP: Alkaline phosphatase; BSA: Bovine serum albumin; CD: Cluster differentiation;
COMP: Cartilage oligomeric matrix protein; CPC: Cetyl pyridinium chloride;
DMEM: Dulbecco’s modified Eagle’s media; ELISA: Enzyme-linked
immunosorbent assay; FBS: Fetal bovine serum; FCS: Fetal calf serum;
FITC: Fluorescein isothiocyanate; GAG: Glycosaminoglycan; IGF: Insulin-like growth
factor; MPC: Mesenchymal progenitor cell; MSC: Mesenchymal stem cell;
PBS: Phosphate-buffered saline; PG: Proteoglycan; PI: Propidium iodide; PNP: Para-
nitrophenyl phosphate; PPS: Pentosan polysulfate; TBA: Tetrabutyl ammonium;
TGF: Transforming growth factor
Acknowledgements
The authors gratefully acknowledge the contribution of Mark Van der Hoek
of the David R. Gunn Genomics Suite, South Australia Health and Medical
Research Institute, Adelaide South Australia, for subjecting the RNA isolated
from the PPS primed and non-primed MPCs to NEXTflex™ Rapid Illumina
Directional RNA-Sequencing and providing data analysis of the results. We
also thank Professor Silviu Itescu CEO of Mesoblast Ltd for permission to use
the immune-selected human STRO-1+ MPC for this study and acknowledge
that Mesoblast Ltd have been granted international patent rights for the
commercial application of these cells.
Funding
This project was partially funded with a research grant provided by
Proteobioactives Pty. Ltd.
Availability of data and materials
All the data and material not included in this report are available from the
authors on request. However, some material is presently archived by
Proteobioactives Pty. Ltd. but would be made available on written request.
Authors’ contributions
PG was responsible for the design and execution of the study and
contributed to the preparation of the manuscript. JW, SS, and SP were
responsible for undertaking the laboratory studies required under the
supervision of PG, SG, and ACWZ, who also contributed to the editing of the
manuscript. CD and TG provided advice on the background and clinical
interpretation of the results and contributed to the editing of the
manuscript. All authors read and approved the final manuscript.
Wu et al. Stem Cell Research & Therapy  (2017) 8:278 Page 13 of 15
Ethics approval and consent to participate
Ethics approval and consent to participate was obtained from the Human




PG is a Director of Proteobioactives Pty. Ltd. but does not hold shares in the
company. JW and SS were employees of Proteobioactives Pty. Ltd. but do
not hold shares in the Company. The remaining authors declare that they
have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Proteobioactives Pty. Ltd., PO Box 174, Balgowlah, Sydney, New South Wales
2093, Australia. 2Myeloma Research Laboratory, Faculty of Health and Medical
Sciences, University of Adelaide and the Cancer Theme, South Australia
Health and Medical Research Institute, Adelaide, South Australia 5000,
Australia. 3Department of Surgery, Monash University, Clayton, Victoria 3168,
Australia. 4Department of Neurosurgery, Monash Medical Centre, Clayton,
Victoria 3168, Australia. 5The Ritchie Centre, Hudson Institute of Medical
Research, Monash University, Clayton, Victoria 3168, Australia. 6Mesenchymal
Stem Cell Laboratory, Adelaide Medical School, Faculty of Health and
Medical Sciences, University of Adelaide, Adelaide, South Australia 5000,
Australia. 7Present address: Minomic International Ltd, Suite 2, 75 Talavera Rd,
Macquarie Park, NSW 2113, Australia. 8Present address: School of
Mathematical and Physical Sciences, Faculty of Science, University of
Technology Sydney, Broadway, PO Box 123, Sydney, NSW 2007, Australia.
Received: 10 July 2017 Revised: 6 November 2017
Accepted: 10 November 2017
References
1. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641–50.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of
adult human mesenchymal stem cells. Science. 1999;284:143–7.
3. Bianco P, Rimininucci M, Gronthos S, Robey PG. Bone marrow stromal stem
cells: nature, biology and potential applications. Stem Cells. 2001;19:180–92.
4. Zannettino ACW, Paton S, Kortesidis A, Khor F, Itescu S, Gronthos S. Human
Mulipotential Stromal Stem Cells are Derived from a Discrete Subpopulation
of STRO-1bright/CD34-/CD45-/Glycophorin-A- Bone Marrow Cells.
Haematologica. 2007;92:1707–8.
5. Tang X, Fan L, Pei M, Zeng L, Ge Z. Evolving concepts of chondrogenic
differentiation: history, state-of-the-art and future perspectives. Eur Cell
Mater. 2015;30:12–27.
6. Ma S, Xie W, Yuan B, Shi Y, Wang Y. Immunology of mesenchymal stem
cells. Cell Death Differ. 2014;21:216–25.
7. Caplan A. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009;
217:318–24.
8. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent
stromal cells: the state of trans differentiation and modes of tissue
repair—current views. Stem Cells. 2007;25:2896–902.
9. De Becker A, Riet IV. Homing and migration of mesenchymal stromal cells:
how to improve the efficacy of cell therapy. World J Stem Cells. 2016;8:73–87.
10. Tuan RS, Boland G, Tuli R. Adult mesenchymal stem cells and cell based
tissue engineering. Arthritis Res Ther. 2003;5:32–45.
11. Chen FH, Tuan RS. Mesenchymal stem cells in arthritic diseases. Arthritis Res
Ther. 2008;10:233–45.
12. Jorgensen C, Djouad F, Bouffi C, Mrugala D, et al. Multipotent mesenchymal
stromal cells in articular diseases. Best Pract Res Clin Rheumatol. 2008;22:269–84.
13. Barry F, Murphy M. Mesenchymal stem cells in joint disease and repair.
Nat Rev Rheumatol. 2013;9:584–94.
14. Zeckser J, Wolff M, Tucker J, Goodwin J. Multipotent mesenchymal stem cell
treatment for discogenic low back pain and disc degeneration. Strm Cells
Int. 2016;2016:3908389. doi:10.1155/2016/3908389.
15. Oehme D, Goldschlager T, Ghosh P, Rosenfeld JV, Jenkin G. Cell-based
therapies used to treat lumbar degenerative disc disease: a systematic
review of animal studies and human clinical trials. Stem Cell Int. 2015;2015:
946031. doi:10.1155/2015/946031.
16. Richardson SM, Kalamegam G, Pushparaj PN, Matta C, Memic A, et al.
Mesenchymal stem cells in regenerative medicine: focus on articular
cartilage and intervertebral disc degeneration. Methods. 2016; doi:10.1016/j.
ymeth.2015.09.015.
17. Murphy JM, Fink DJ, Hunziker EB, Barry FB. Stem cell therapy in a caprine
model of osteoarthritis. Arthritis Rheum. 2003;48:3464–74.
18. Lee KBL, Hui JHP, Song IC, Ardany L, Lee EH. Injectable mesenchymal stem cell
therapy for large cartilage defects—a porcine model. Stem Cells. 2007;25:2964–71.
19. Pelttari K, Winter A, Steck E, Goetzke K, Hennig T, et al. Premature induction
of hypertrophy during in vitro chondrogenesis of human mesenchymal
stem cells correlates with calcification and vascular invasion after ectopic
transplantation in SCID mice. Arthritis Rheum. 2006;54:3254–66.
20. Ahmed N, Stanford WI, Kandel RA. Mesenchymal and progenitor cells for
cartilage repair. Skeletal Radiology. 2007: doi 10.1007/s00256-007-0333-3.
21. Ghosh P, Wu J, Shimmon S, Zannettino AC, Gronthos S, Itescu S. Pentosan
polysulfate promotes proliferation and chondrogenic differentiation of adult
human bone marrow-derived mesenchymal precursor cells. Arthritis Res
Ther. 2010;12(1):R28.
22. Goldschlager T, Ghosh P, Zannettino A, Gronthos S, Rosenfeld J, Itescu S, et
al. Cervical motion preservation using mesenchymal progenitor cells and a
novel chondrogenic agent, pentosan polysulfate—a preliminary study in an
ovine model. Neurosurg Focus. 2010;28(6):E4.
23. Oehme D, Ghosh P, Goldschlager T, et al. Reconstitution of degenerated
ovine lumbar discs by STRO-3-positive allogeneic mesenchymal precursor
cells combined with pentosan polysulfate. J Neurosurg Spine. 2016;22:1–12.
24. Oehme D, Ghosh P, Shimmon S, et al. Mesenchymal progenitor cells
combined with pentosan polysulfate mediating disc regeneration at the
time of microdiscectomy: a preliminary study in an ovine model. J
Neurosurg Spine. 2014;20(6):657–69.
25. Gronthos S, Zannettino AC, Hay SJ, Shi S, Graves SE, Kortesidis A, Simmons
PJ. Molecular and cellular characterisation of highly purified stromal stem
cells derived from human bone marrow. J Cell Sci. 2003;116:1827–35.
26. Farndale RW, Buttle DJ, Barrett AJ. Improved quantitation and discrimination
of sulphated glycosaminoglycans by use of dimethylmethylene blue.
Biochim Biophys Acta. 1986;883(2):173–7.
27. Kim YJ, Sah RL, Doong JY, Grodzinsky AJ. Fluorometric assay for DNA in
cartilage explants using Hoechst 33258. Anal Biochem. 1988;174:168–76.
28. Castellot JJ, Wong K, Herman B, Hoover RL, Albertini DF, et al. Binding and
internalization of heparin by vascular smooth muscle cells. J Cellular Physiol.
1985;124:13–20.
29. Patel MK, Refson JS, Schachter M, Hughes AD. Characterization of [3H]-
heparin binding in human smooth muscle cells and its relationship to the
inhibition of DNA synthesis. Br J Pharmacol. 1999;127:361–8.
30. Herbert CA, Kwa MSG, Hermsen HPH. Risk factors in the development of
stem cell therapy. J Transl Med. 2011;9:29.
31. Phinney DG, Kopen G, Righter W, Webster S, Tremain N, Prockop DJ. Donor
variation in the growth properties and osteogenic potential of human
marrow stromal cells. J Cell Biochem. 1999;75(3):424–36.
32. Lee KA, Shim W, Paik MJ, Lee SC, Shin JY, Ahn YH, et al. Analysis of changes
in the viability and gene expression profiles of human mesenchymal
stromal cells over time. Cytotherapy. 2009;11:688–97.
33. Shin TH, Lee S, Choi KR, Lee DY, Kim Y, Jeong M, et al. Quality and freshness
of human bone marrow-derived mesenchymal stem cells decreases over
time after trypsininization and storage in phosphate buffered saline. Nat Sci
Rep. 2017;7:1106. doi:10.1038/s41598-017-01315-0.
34. Lee HJ, Choi BH, Min B-H, Park SR. Changes in surface markers of human
mesenchymal stem cells during the chondrogenic differentiation and de-
differentiation process in vitro. Arthritis Rheum. 2009;60:2325–32.
35. Schrage A, Loddenkemper C, Erben U, Lauer U, Hausdorf G, Jungblut PR,
et al. Murine CD146 is widely expressed on endothelial cells and is
recognized by the monoclonal antibody ME-9 F1. HistchemCell Biol. 2006;
129:441–51.
36. Crisan M, Yap S, Castella L, Chen C-W, Corselli M, et al. A perivascular origin for
mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3:301–13.
37. Tu T, Zhang C, Yan H, Luo Y, Kong R, Wen P, et al. CD146 acts as a novel
receptor for netrin-1 in promoting angiogenesis and vascular development.
Cell Res. 2015;25:275–87.
Wu et al. Stem Cell Research & Therapy  (2017) 8:278 Page 14 of 15
38. Harkness L, Zaher W, Ditzel W, Isa A, Kassem M. CD146/MCAM defines
functionality of human bone marrow stromal stem cell populations. Stem
Cell Res Ther. 2016;7:4. doi:10.1186/s13287-015-0266-z.
39. Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation.
Arthritis Res Ther. 2003;5:94–103.
40. Wenstrup RJ, Florer JB, Brunskill EW, Bell SM, Chervoneva I, Birk DE. Type V
collagen controls the initiation of collagen fibre assembly. J Biological
Chem. 2004;279:53331–7.
41. Smith HH, Calderon R, Song Y, Tuan RS, Chen FH. Cartilage oligomeric
matrix protein enhances matrix assembly during chondrogenesis of human
mesenchymal stem cells. J Cell Biochem. 2012;4:1245–52.
42. Pacifici M, Koyama E, Shibukawa Y, Tamamura Y, et al. Cellular and
molecular mechanisms of synovial joint and articular cartilage formation.
Ann NY Acad Sci. 2006;1068:74–86.
43. Busch SJ, Sassone-Corsi P. Fos, Jun, and CREB basic domain peptides have
intrinsic DNA-binding activity enhanced by a novel stabilizing factor.
Oncogene. 1990;5:1549–56.
44. Wagner EF, Karsenty G. Genetic control of skeletal development. Curr Opin
Gene Dev. 2002;2:389–406.
45. Busch SJ, Martin GA, Barnhart RL, Mano M, Cardin AD, Jackson RL. Trans-
repressor activity of nuclear glycosaminglycans on Fos and Jun/AP-1
oncoprotein-mediated transcription. J Cell Biology. 1992;116(1):31–2.
46. Pintus G, Tadolini B, Maioi M, Posadino AM, Bennardini F, et al. Heparin
inhibits phorbol ester-induced ornithine decarboxylase gene expression in
endothelial cells. FEBS Lett. 1996;423:98–104.
47. Gilotti AC, Nimlamool W, Pugh R, Slee JB, Barthol TC, Miller EA, et al.
Heparin responses in vascular smooth muscle cells involves cGMP
dependent protein kinase (PKG). J Cell Physiol. 2014;12:2142–52.
48. Farwell SL, Kanyl D, Hamel M, Slee JG, Miller EA, Cipolle MD, et al. Heparin
decreases in tumor necrosis factor a (TNF-alpha)-induced endothelial stress
response requires transmembrane protein 184A and induction of dual
specificity phosphatase-1. J Biol Chem. 2016;291:5342–54.
49. Furue MK, Na J, Jackson JP, Okamoto T, Jones M, Baker D, Hata R, Moore HD,
Sato JD, Andrews PW. Heparin promotes the growth of human embryonic stem
cells in a defined serum-free medium. Proc Natl Acad Sci. 2008;105:13409–14.
50. Sasaki N, Okishio K, Ui-Tei K, Saigo K, Kinoshita-Toyoda A, Toyoda H,
Nishimura S, et al. Heparan sulfate regulates self-renewal and pluripotency
of embryonic stem cells. J Biol Chem. 2008;283:3594–606.
51. Uygun BE, Stojsih SE, Matthew HW. Effects of immobilized
glycosaminoglycans on the proliferation and differentiation of
mesenchymal stem cells. Tissue Eng Part A. 2009;15:3499–512.
52. Ling L, Camilleri ET, Helledie T, Samsonra RM, Titmarsh DM, et al. Effect of
heparin on the biological properties and molecular signature of human
mesenchymal stem cells. Gene. 2016;576:292–303.
53. Jacbsson O, Kuver T, Granath K. Characterization of xylan sulphate by size
exclusion chromatography. J Liquid Chromatography. 1986;9:1541–61.
54. Capila I, Linhardt RJ. Heparin–protein interactions. Angew Chem Int Ed.
2002;47:390–412.
55. Ghosh P, Smith M, Wells C. Second line agents in osteoarthritis. In: Dixon JS,
Furst DE, editors. Second-line agents in the treatment of rheumatic diseases.
New York: Dekker; 1992. p. 363–427.
56. Teichman JMH. The role of pentosan polysulfate in treatment approaches
for interstitial cystitis. Urology. 2002;4 Suppl 1:S21–7.
57. Shlotmann W. Uber den Heilerfolg der Tendovaginitis fibrinosa unter SP-
54—Applikation. Med Welt H. 1969;25:1444–9.
58. Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of
pentosan polysulfate for its treatment. Seminars Arthritis Rheum. 1999;28(4):211–67.
59. Ghosh P, Edelman J, March L, Smith M. Effects of pentosan polysulfate in
osteoarthritis of the knee: a randomized, double blind, placebo-controlled
pilot study. Curr Ther Res. 2005;66:552–71.
60. Kumagai K, Shurabe K, Miyata N, Murata M, Yamauchi A, Kataoka Y. et al.
Sodium pentosane polysulfate resulted in cartilage improvement in knee
osteoarthritis—an open clinical trial. BMC Clinical Pharmacol. 2010;10:7.
http://www.biomedcentral.com/1472-6904/10/7.
61. Herrero LJ, Foo S-S, Sheng K, Chen WC, Forwood MS, et al. Pentosan polysulfate:
a novel glycosaminoglycan-like molecule for effective treatment of alphavirus-
induced cartilage destruction and inflammatory disease. J Virol. 2015;89:8063–76.
62. Daly CD, Ghosh P, Zannettino AC, Badal T, Shimmon R, Jenkin G, Jain K,
Oehme D, et al. Mesenchymal progenitor cells primed with pentosan
polysulfate promote lumbar intervertebral disc regeneration in an ovine
model of microdiscectomy. Spine J. 2017(in press).
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Wu et al. Stem Cell Research & Therapy  (2017) 8:278 Page 15 of 15
